Dexamethasone (DEX) has been extensively employed for the treatment of pregnancy disorders related to preterm birth. However, the precise mechanism by which prenatal DEX exposure affects foetal development remains unclear. This study delves into investigating the influence of DEX and ferroptosis inhibitors on the activity and ferroptosis level of placental trophoblast cells through various in vitro tests. The results demonstrated that prenatal administration of DEX led to a substantially increased ferroptosis level in placental tissues. DEX decreased cell viability, increased iron accumulation and increased lipid peroxidation. Treatment with ferroptosis inhibitors reversed these effects. Mechanistically, DEX regulated autophagy and modulated the protein levels of AMPKα/BECN1 and ATG5/ATG7/NCOA4 signalling pathways by inhibiting its receptor GRα. Additionally, autophagy activation mediated through the AMPKα/BECN1 axis and ferritin degradation via ATG5/ATG7/NCOA4 signalling was associated with DEX‐induced ferroptosis. Overall, this study provides experimental evidence supporting the detrimental side effects of DEX on preterm pregnancy‐related disorders. It identified that AMPKα/BECN1 and ATG5/ATG7/NCOA4 were key pathways by which DEX induced autophagy‐dependent ferroptosis in placental trophoblast cells.
Endometrial Cancer is a prevalent malignant tumor in gynecology, marked by high incidence and poor prognosis. The discovery of cuproptosis, a copper-depend
Cervical cancer remains a major global health burden, particularly in settings with limited access to screening and human papillomavirus (HPV) vaccination. Although surgery and chemoradiation can achieve high cure rates in early-stage disease, outcomes for persistent, recurrent, or metastatic disease remain poor, highlighting the need for more effective and individualized systemic therapies. Immune checkpoint inhibitors have become integral to the treatment landscape, yet clinical benefit is modest for many patients and biomarker guidance remains imperfect. In this review, we define “precision management” as the biomarker- and microenvironment-informed selection of immunotherapy-based regimens across disease settings, coupled with rational combination design to overcome resistance. We synthesize cervical cancer–specific immune biology, including HPV-mediated immune evasion, and critically compare pivotal positive and negative clinical trials to explain why certain combinations succeed or fail. Finally, we discuss translational enablers—robust biomarkers, optimized delivery platforms, and functional models such as organoids—that may accelerate evidence-based personalization of immunotherapy in cervical cancer.
Ovarian cancer ranks as the third most common gynecological malignancy, yet it has the highest mortality and recurrence rates among all gynecologic cancers